NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
Abstract Although multiple cellular pathways have been implicated in a-Synuclein (a-syn)-associated Parkinson’s disease (PD), the role of lipid metabolism remains elusive. Using the Drosophila system as a genetic screening tool, we identified mino , which encodes the mitochondrial isoform of the lipid synthesis enzyme glycerol 3-phosphate acyltransferase (GPAT), as a potent modifier of a-syn. Silencing the expression of mino significantly suppresses a-syn-induced PD phenotypes in Drosophila , including dopaminergic neuronal loss and locomotion defects as well as circadian rhythm-related activities, whereas mino overexpression yields opposite effects. Mechanistically, we found that mino modulates the levels of mitochondrial reactive oxygen speciesand lipid peroxidation. Importantly, treatment of a-syn-expressing flies with FSG67, a GPAT inhibitor, reproduces the benefits of mino knockdown. FSG67 also inhibited a-syn aggregation and lipid peroxidation in mouse primary neurons transfected with a-syn preformed fibrils. Our study elucidates an important factor contributing to a-syn toxicity and offers a novel therapeutic direction for PD.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.